中华检验医学杂志
中華檢驗醫學雜誌
중화검험의학잡지
CHINESE JOURNAL OF LABORATORY MEDICINE
2010年
8期
747-751
,共5页
易斌%周欢群%姚润%肖志强
易斌%週歡群%姚潤%肖誌彊
역빈%주환군%요윤%초지강
鼻咽癌%ELISA%自身抗体%诊断%标志物
鼻嚥癌%ELISA%自身抗體%診斷%標誌物
비인암%ELISA%자신항체%진단%표지물
Nasopharyngeal carcinoma%ELISA%Autoantibody%Diagnosis%Marker
目的 以血清蛋白质组学方法筛选到的4种鼻咽癌患者自身抗体(Rho-GDI-2、HSP70、CK19和LAP3)为对象,分析其诊断鼻咽癌的价值.方法 通过对封闭条件、抗原浓度及血清稀释度等条件进行优化,建立鼻咽癌患者血清自身抗体的ELISA检测方法,采用该方法分别检测Rho-GDI-2、HSP70、CK19和LAP3自身抗体在36例鼻咽癌患者、20例其他肿瘤患者及20名健康人血清中的浓度,采用统计学方法分析其判别鼻咽癌的敏感度和特异度.结果 鼻咽癌患者血清中4种抗体的含量明显高于健康人(鼻咽癌患者CK19、Rho-GDI-2、HSP70、LAP3的A450值分别为0.188 8±0.047 3、0.240 5±0.024 7、0.116 8±0.025 3、0.2769±0.0442;健康人A450值分别为0.010 5±0.0044、0.1053±0.016 9、0.098 6±0.014 0、0.149 8±0.033 1;F值分别为4.869、15.919、10.331、6.369;P值分别为0.010、0.000、0.000、0.003).Rho-GDI-2、HSP70、CK19和LAP3抗体判别鼻咽癌的敏感度分别为85.0%、75.0%、75.0%和75.0%,特异度分别为58.9%、80.4%、58.9%和57.1%准确性分别为76.8%、76.8%、69.6%和67.9%.以单个自身抗体作为判别鼻咽癌的指标,Rho-GDI-2抗体具有更高的敏感度,而HSP70抗体的特异度最高.4种抗体联合应用,判别鼻咽癌的敏感度和特异度可达94.4%和95.0%.结论 采用ELISA方法检测Rho-GDI-2、HSP70、CK19和LAP3自身抗体有助于鼻咽癌的筛杳和诊断.
目的 以血清蛋白質組學方法篩選到的4種鼻嚥癌患者自身抗體(Rho-GDI-2、HSP70、CK19和LAP3)為對象,分析其診斷鼻嚥癌的價值.方法 通過對封閉條件、抗原濃度及血清稀釋度等條件進行優化,建立鼻嚥癌患者血清自身抗體的ELISA檢測方法,採用該方法分彆檢測Rho-GDI-2、HSP70、CK19和LAP3自身抗體在36例鼻嚥癌患者、20例其他腫瘤患者及20名健康人血清中的濃度,採用統計學方法分析其判彆鼻嚥癌的敏感度和特異度.結果 鼻嚥癌患者血清中4種抗體的含量明顯高于健康人(鼻嚥癌患者CK19、Rho-GDI-2、HSP70、LAP3的A450值分彆為0.188 8±0.047 3、0.240 5±0.024 7、0.116 8±0.025 3、0.2769±0.0442;健康人A450值分彆為0.010 5±0.0044、0.1053±0.016 9、0.098 6±0.014 0、0.149 8±0.033 1;F值分彆為4.869、15.919、10.331、6.369;P值分彆為0.010、0.000、0.000、0.003).Rho-GDI-2、HSP70、CK19和LAP3抗體判彆鼻嚥癌的敏感度分彆為85.0%、75.0%、75.0%和75.0%,特異度分彆為58.9%、80.4%、58.9%和57.1%準確性分彆為76.8%、76.8%、69.6%和67.9%.以單箇自身抗體作為判彆鼻嚥癌的指標,Rho-GDI-2抗體具有更高的敏感度,而HSP70抗體的特異度最高.4種抗體聯閤應用,判彆鼻嚥癌的敏感度和特異度可達94.4%和95.0%.結論 採用ELISA方法檢測Rho-GDI-2、HSP70、CK19和LAP3自身抗體有助于鼻嚥癌的篩杳和診斷.
목적 이혈청단백질조학방법사선도적4충비인암환자자신항체(Rho-GDI-2、HSP70、CK19화LAP3)위대상,분석기진단비인암적개치.방법 통과대봉폐조건、항원농도급혈청희석도등조건진행우화,건립비인암환자혈청자신항체적ELISA검측방법,채용해방법분별검측Rho-GDI-2、HSP70、CK19화LAP3자신항체재36례비인암환자、20례기타종류환자급20명건강인혈청중적농도,채용통계학방법분석기판별비인암적민감도화특이도.결과 비인암환자혈청중4충항체적함량명현고우건강인(비인암환자CK19、Rho-GDI-2、HSP70、LAP3적A450치분별위0.188 8±0.047 3、0.240 5±0.024 7、0.116 8±0.025 3、0.2769±0.0442;건강인A450치분별위0.010 5±0.0044、0.1053±0.016 9、0.098 6±0.014 0、0.149 8±0.033 1;F치분별위4.869、15.919、10.331、6.369;P치분별위0.010、0.000、0.000、0.003).Rho-GDI-2、HSP70、CK19화LAP3항체판별비인암적민감도분별위85.0%、75.0%、75.0%화75.0%,특이도분별위58.9%、80.4%、58.9%화57.1%준학성분별위76.8%、76.8%、69.6%화67.9%.이단개자신항체작위판별비인암적지표,Rho-GDI-2항체구유경고적민감도,이HSP70항체적특이도최고.4충항체연합응용,판별비인암적민감도화특이도가체94.4%화95.0%.결론 채용ELISA방법검측Rho-GDI-2、HSP70、CK19화LAP3자신항체유조우비인암적사묘화진단.
Objective To analyze the diagnostic value of 4 serum autoantibodies in nasopharyngeal carcinoma patients (anti-Rho-GDI-2, -HSP70, -CK19 and -LAP3 antibodies) using a serological proteomic approach. Methods The conditions for blocking, antigen concentrations and serum dilution were optimized to establish the ELISA method for detection of serum autoantibodies for Rho-GDI-2, HSP70, CK19 and LAP3. The serum concentrations of these autoantibodies were detected by the established method in 36 NPC patients, 20 other cancer patients and 20 healthy individuals. The statistical analysis was used to evaluate the diagnostic value of the 4 serum autoantibodies. Results The concentrations of 4 serum autoantibodies in the NPC patients were significantly higher than those in the healthy individuals(A450 values in NPC group of CK19, Rho-GDI-2, HSP70, LAP3 were 0. 188 8 ±0.047 3, 0.240 5 ± 0.024 7, 0. 116 8 ±0.025 3, 0.276 9 ±0.044 2 repectively. A450 values in healthy control group were 0.010 5 ±0.004 4, 0. 105 3 ±0. 016 9, 0. 098 6 ± 0. 014 0, 0. 149 8 ± 0. 033 1 respectively. F values were 4. 869, 15. 919, 10. 331,6. 369, respectively. P values were 0. 010, 0. 000, 0. 000, 0. 003, respectively). The sensitivities of antiRho-GDI-2, anti-HSP70, anti -CK19 and anti -LAP3 autoantibodies for diagnosis of NPC was 85.0%,75.0%, 75.0% and 75.0%, respectively, and the specificities were 58.9%, 80. 4%, 58. 9% and 57. 1%, respectively, anti-Rho-GDI-2 and anti-HSP70 achived the highest sensitivity and specificity respectively when single marker was analyzed. The sensitivity and specificity were 94. 4% and 95. 0%respectively when 4 markers was combined for analysis. Conclusion Detection of serum anti-Rbo-GDI-2,anti-HSP70, anti-CK19 and anti-IAP3 auotantibedios by ELISA may be of help in the screening and diagnosis for NPC.
